References
  1. Marjanska A, Drogosiewicz M, Demowska-Baginska B, Pawinska-Wasikowska K, Balwierz W, Bobeff K, Mlynarski W, Mizia-Malarz A, Raciborska A, Wysocki M, Styczynski J. Nivolumab for the treatment of advanced pediatric malignancies. Anticancer Research. 2020 (40)12:7095-7100.
  2. Aldrink JH, Polites SF, Austin M. Pediatric melanoma - diagnosis, management, and anticipated outcomes. 2021. Sure Once Clin N Am. 2021;373-388.
  3. Batra S. Spitzoid melanoma of childhood: a case series and review.Future Medicine. 2015; 2(2):121-125.
  4. Ryan AL et al. Malignant melanoma in children and adolescents treated in pediatric oncology centers: an Australian and New Zealand children’s oncology group (ANZCHOG) study. Frontiers in Oncology. 2021;11:1-8.
  5. Pampena R, Kyrgidis A, Lallas A, Moscarella E, Argenziano G, and Longo, C. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. Journal of the American Academy of Dermatology. 2017;(77)5: 938 - 945.6.
  6. Hawryluk EB, Moustafa D, Bartenstein D, Brahmbhatt M., Cordoro K., Gardner L., Gauthier A, Grossman D, Gupta D, Hunt RD, Jen M, Kao P, Kruse LL, Lawley L. P., London, W. B., Mansour, D., O’Haver, J. A., Phung, T., Pope, E., Price, H. N., Rogers, T, Shah SD, Wolner Z, Huang J, Marghoob AA. A retrospective multicenter study of fatal pediatric melanoma. Journal of the American Academy of Dermatology. 2020;83(5).
  7. El Sharouni MA, Rawson RV, Potter AJ, Paver EC, Wilmott JS, Witkamp AJ, Sigurdsson V, van Diest PJ, Scolyer RA, Thompson JF, Lo SN, van Gils CH. Melanomas in children and adolescents: Clinicopathologic features and survival outcomes. J Am Acad Dermatol. 2023;88(3):609-616.
  1. Bartenstein, DW, Kelleher, CM, Friedmann AM, Duncan LM, Tsao H, Sober A J, Hawryluk EB. Contrasting features of childhood and adolescent melanomas. Pediatric dermatology. 2018:35 (3), 354-360.
  2. Moore-Olufemi S, Herzog C, Warneke C, Gershenwald JE, Mansfield P, Ross M, Prieto V, Lally KP, Hayes-Jordan A. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg. 2011;253(6):1211-5
  3. Pol-Rodriquez M., Lee S., Silvers DN, Celebi JT. Influence of age on survival in childhood spitzoid melanomas. American Cancer Society. 2007;109(8):1579-1583.
  4. Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL. Nivolumab in children and young adults with relapsed or refractory solid tumors or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21(4):541-550.
  5. Richards MK, Czechowicz J, Goldin AB, et al. Survival and Surgical Outcomes for Pediatric Head and Neck Melanoma. JAMA Otolaryngoly Head Neck Surg. 2017;143(1):34–40.
  6. Pappo AS, McPherson V, Pan H, Wang F, Wang L, Wright T, Hussong M, Hawkins D, Kaste SC, Davidoff AM, Bahrami A. A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions. Cancer. 202;127(20):3825-3831.
  7. Cordoro KM, Gupta D, Frieden IJ, McCalmont T, Kashani-Sabet M. Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol. 2013;68(6):913-25.
  8. Cymerman RM, Shao Y, Wang K, Zhang Y, Murzaku EC, Penn LA, Osman I, Polsky D. De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival. J Natl Cancer Inst. 2016;108(10).
  9. Lallas A, Kyrgidis A, Ferrara G, Kittler H, Apalla Z, Castagnetti F, Longo C, Moscarella E, Piana S, Zalaudek I, Argenziano G. Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. Lancet Oncol. 2014;15(4):178-83.